Financial Performance - The company's revenue increased by 35.4% to RMB 2,381.9 million for the six months ended June 30, 2024, compared to RMB 1,759.5 million in the same period last year[3]. - Hospital business revenue rose by 37.2% to RMB 2,307.5 million, up from RMB 1,681.8 million year-on-year[3]. - Gross profit increased by 32.5% to RMB 756.4 million, compared to RMB 570.8 million in the previous year[3]. - EBITDA grew by 28.7% to RMB 647.0 million, up from RMB 502.6 million year-on-year[3]. - Operating profit rose by 22.4% to RMB 513.7 million, compared to RMB 419.6 million in the same period last year[3]. - Non-IFRS adjusted net profit increased by 15.5% to RMB 400.6 million, up from RMB 346.7 million year-on-year[3]. - The net profit attributable to the owners of the company was RMB 384,571 thousand, compared to RMB 334,136 thousand in 2023, reflecting a growth of 15.1%[125]. - Basic and diluted earnings per share for the period were both RMB 0.61, up from RMB 0.53 in the same period last year[125]. Operational Highlights - The company manages or operates 16 hospitals focused on oncology, with 4 tertiary hospitals and 12 secondary hospitals across 13 cities in 8 provinces in China[10]. - The total number of surgeries performed was 46,095, with surgical revenue increasing by 38.6% compared to the previous year[14]. - Outpatient service revenue reached RMB 812.8 million, up 49.6% year-over-year, while inpatient service revenue was RMB 1,494.6 million, reflecting a 31.3% increase[14]. - Oncology-related business revenue grew by 31.1% to RMB 1,045.8 million, compared to RMB 797.8 million in the same period last year[17]. - The gross profit for the hospital business was RMB 718.0 million, a 36.8% increase year-over-year, with a stable gross margin of 31.1%[19]. Shareholder Returns and Capital Management - The company plans to repurchase shares up to a total price of RMB 200.0 million depending on market conditions[4]. - The company has distributed a total of approximately RMB 170 million in dividends since its listing in 2020, with RMB 74 million in 2021 and RMB 95 million in 2023[38]. - The board approved a share repurchase plan to buy back shares up to a total price of RMB 200 million, reflecting confidence in the company's business outlook[52]. - The company has maintained a commitment to shareholder returns, with the founder and CEO never having sold shares since the IPO and having increased their holdings by over 3 million shares[38]. Employee and Community Engagement - The group has 7,587 medical professionals as of June 30, 2024, an increase of 104 from December 31, 2023[23]. - The company has provided internal and external training to enhance employee skills and knowledge, with compensation primarily consisting of base salary and performance-related bonuses[105]. - The company is actively involved in community service and healthcare initiatives, enhancing its brand influence and social impact[35]. - Patient satisfaction rate reached 96.9%, an increase of 0.3% compared to 2023, with a goal of achieving 100% satisfaction[26]. Strategic Initiatives and Future Plans - The group plans to establish 1,000 beds at the newly built Dezhou Haijia Hospital, which is set to open in July 2024, with additional new hospitals in Wuxi and Changshu also progressing[29]. - The expansion projects will increase the total bed capacity to over 16,000 once all ongoing and planned expansions are completed[29]. - The group is focused on strengthening the multidisciplinary treatment model for oncology, enhancing clinical research capabilities, and improving diagnostic and treatment technologies[20]. - The group continues to promote the integration of clinical practice and medical research, actively participating in national and provincial key research projects[24]. Financial Position and Assets - Total assets increased by 2.5% to RMB 11,004.5 million as of June 30, 2024, from RMB 10,734.6 million as of December 31, 2023[79]. - Total liabilities decreased by 2.8% to RMB 4,355.7 million as of June 30, 2024, from RMB 4,479.7 million as of December 31, 2023[79]. - Cash and cash equivalents as of June 30, 2024, totaled RMB 236.8 million, with financial products amounting to RMB 498.2 million, resulting in a total of RMB 735.0 million[72]. - Trade receivables increased by 10.6% to RMB 955.8 million as of June 30, 2024, compared to RMB 864.0 million as of December 31, 2023, due to expanded revenue scale[81]. Regulatory and Market Environment - The aging population is expected to drive an increase in age-related diseases, leading to a growing demand for related treatments[47]. - The government is committed to creating a favorable environment for the development of private healthcare, which is seen as a crucial component of China's modernization efforts[44]. - The National Health Commission's plan aims to improve cancer prevention and treatment capabilities, targeting a 5-year survival rate of 46.6% by 2030[46]. - The focus on enhancing clinical specialty capabilities is emphasized, particularly in high-incidence diseases such as cardiovascular diseases and malignant tumors[45].
海吉亚医疗(06078) - 2024 - 中期业绩